94 related articles for article (PubMed ID: 11502748)
1. The Dbl homology domain of BCR is not a simple spacer in P210BCR-ABL of the Philadelphia chromosome.
Kin Y; Li G; Shibuya M; Maru Y
J Biol Chem; 2001 Oct; 276(42):39462-8. PubMed ID: 11502748
[TBL] [Abstract][Full Text] [Related]
2. Differential motility of p190bcr-abl- and p210bcr-abl-expressing cells: respective roles of Vav and Bcr-Abl GEFs.
Daubon T; Chasseriau J; El Ali A; Rivet J; Kitzis A; Constantin B; Bourmeyster N
Oncogene; 2008 Apr; 27(19):2673-85. PubMed ID: 18059343
[TBL] [Abstract][Full Text] [Related]
3. The SH2 domain of P210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells.
Ilaria RL; Van Etten RA
Blood; 1995 Nov; 86(10):3897-904. PubMed ID: 7579359
[TBL] [Abstract][Full Text] [Related]
4. The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation.
Sahay S; Pannucci NL; Mahon GM; Rodriguez PL; Megjugorac NJ; Kostenko EV; Ozer HL; Whitehead IP
Oncogene; 2008 Mar; 27(14):2064-71. PubMed ID: 17922031
[TBL] [Abstract][Full Text] [Related]
5. BCR-ABL and constitutively active erythropoietin receptor (cEpoR) activate distinct mechanisms for growth factor-independence and inhibition of apoptosis in Ba/F3 cell line.
Ahmed M; Dusanter-Fourt I; Bernard M; Mayeux P; Hawley RG; Bennardo T; Novault S; Bonnet ML; Gisselbrecht S; Varet B; Turhan AG
Oncogene; 1998 Jan; 16(4):489-96. PubMed ID: 9484838
[TBL] [Abstract][Full Text] [Related]
6. Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24 homology domains but not the pleckstrin homology one.
Martinelli G; Amabile M; Giannini B; Terragna C; Ottaviani E; Soverini S; Saglio G; Rosti G; Baccarani M
Haematologica; 2002 Jul; 87(7):688-94; discussion 694. PubMed ID: 12091118
[TBL] [Abstract][Full Text] [Related]
7. p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia.
Mian AA; Metodieva A; Najajreh Y; Ottmann OG; Mahajna J; Ruthardt M
Haematologica; 2012 Feb; 97(2):251-7. PubMed ID: 22058195
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
Matulonis U; Salgia R; Okuda K; Druker B; Griffin JD
Exp Hematol; 1993 Oct; 21(11):1460-6. PubMed ID: 8405226
[TBL] [Abstract][Full Text] [Related]
9. Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase.
Reckel S; Gehin C; Tardivon D; Georgeon S; Kükenshöner T; Löhr F; Koide A; Buchner L; Panjkovich A; Reynaud A; Pinho S; Gerig B; Svergun D; Pojer F; Güntert P; Dötsch V; Koide S; Gavin AC; Hantschel O
Nat Commun; 2017 Dec; 8(1):2101. PubMed ID: 29235475
[TBL] [Abstract][Full Text] [Related]
10. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
[TBL] [Abstract][Full Text] [Related]
11. BCR-ABL tyrosine kinase is autophosphorylated or transphosphorylates P160 BCR on tyrosine predominantly within the first BCR exon.
Liu J; Campbell M; Guo JQ; Lu D; Xian YM; Andersson BS; Arlinghaus RB
Oncogene; 1993 Jan; 8(1):101-9. PubMed ID: 8423987
[TBL] [Abstract][Full Text] [Related]
12. Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr-abl positive 32D myeloid leukemia cells.
Guo XY; Cuillerot JM; Wang T; Wu Y; Arlinghaus R; Claxton D; Bachier C; Greenberger J; Colombowala I; Deisseroth AB
Oncogene; 1998 Aug; 17(7):825-33. PubMed ID: 9779999
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of GEF activity of Bcr protein DH domain].
Miroshnychenko DO; Teleheiev HD; Maliuta SS
Ukr Biokhim Zh (1999); 2007; 79(5):116-21. PubMed ID: 18357784
[TBL] [Abstract][Full Text] [Related]
14. Effect of Bcr sequences on the cellular function of the Bcr-Abl oncoprotein.
McWhirter JR; Wang JY
Oncogene; 1997 Oct; 15(14):1625-34. PubMed ID: 9349495
[TBL] [Abstract][Full Text] [Related]
15. p38 MAPK-mediated activation of NF-kappaB by the RhoGEF domain of Bcr.
Korus M; Mahon GM; Cheng L; Whitehead IP
Oncogene; 2002 Jul; 21(30):4601-12. PubMed ID: 12096337
[TBL] [Abstract][Full Text] [Related]
16. Invadopodia and rolling-type motility are specific features of highly invasive p190(bcr-abl) leukemic cells.
Daubon T; Rochelle T; Bourmeyster N; Génot E
Eur J Cell Biol; 2012; 91(11-12):978-87. PubMed ID: 22717125
[TBL] [Abstract][Full Text] [Related]
17. A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells.
Kabarowski JH; Allen PB; Wiedemann LM
EMBO J; 1994 Dec; 13(24):5887-95. PubMed ID: 7813429
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine phosphorylation of P160 BCR by P210 BCR-ABL.
Lu D; Liu J; Campbell M; Guo JQ; Heisterkamp N; Groffen J; Canaani E; Arlinghaus R
Blood; 1993 Aug; 82(4):1257-63. PubMed ID: 8353288
[TBL] [Abstract][Full Text] [Related]
19. Association of Bcr-Abl with the proto-oncogene Vav is implicated in activation of the Rac-1 pathway.
Bassermann F; Jahn T; Miething C; Seipel P; Bai RY; Coutinho S; Tybulewicz VL; Peschel C; Duyster J
J Biol Chem; 2002 Apr; 277(14):12437-45. PubMed ID: 11790798
[TBL] [Abstract][Full Text] [Related]
20. P210 BCR-ABL is complexed to P160 BCR and ph-P53 proteins in K562 cells.
Campbell ML; Li W; Arlinghaus RB
Oncogene; 1990 May; 5(5):773-6. PubMed ID: 2140598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
